Titan Medical Inc. Appoints Dr. Carlo Camargo Passerotti to Its Medical Advisory Board
TORONTO, ONTARIO -- (MARKET WIRE) -- 05/18/11 -- Titan Medical Inc. ("the Company") (TSX VENTURE: TMD) announced today that Dr. Carlo Camargo Passerotti, M.D., PhD was appointed to the Company's Medical Advisory Board.
"We are very pleased to welcome Dr. Passerotti as the first international member on our renowned group of medical advisors," said Dr. Reiza Rayman, President of Titan Medical Inc. "His presence and expertise will considerably expand our future global clinical activities and add an important international perspective, mainly in South America, to our team."
"I am pleased to join Titan Medical's Advisory Board," said Dr. Passerotti. "Titan's novel robotic surgery platform sets out to overcome the shortfalls experienced with robotic surgery devices currently being used in surgery. This is an exciting period in the company's phase of growth and I look forward to assisting in both the technology and clinical development of Amadeus and to positioning it for success in the clinic."
Dr. Carlo Camargo Passerotti currently serves as the Assistant Professor of Urology at the Sao Paulo State University, the Director of Robotic Surgery at the Hospital Alemao Oswaldo Cruz, and the Director of Research in Urology, 9 of July University, Sao Paulo Brazil. Dr. Passerotti earned both his M.D. and PhD at the Federal University of Sao Paulo and continued a Fellowship in Pediatric Urology and Robotic Surgery at Children's Hospital Boston, where he developed laparoscopic and robotic skills. He has earned a number of honors and awards in urology, pediatrics and robotic surgery and has several published papers in leading peer-reviewed journals.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus™, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The current global robotic surgical market size is approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 31, 2011 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer (416) 548-7522 (ext. 151) cleon@titanmedicalinc.com www.titanmedicalinc.com ICR, LLC Sherry Bertner Managing Director (646) 277-1247 Sherry.Bertner@icrinc.com
Source: Titan Medical Inc.
Released May 18, 2011